Shares of H-CYTE, Inc. (OTCMKTS:HCYTD – Get Free Report) traded down 49.5% during mid-day trading on Wednesday . The stock traded as low as $2.02 and last traded at $2.02. 400 shares changed hands during trading, an increase of 288% from the average session volume of 103 shares. The stock had previously closed at $4.00.
H-CYTE Price Performance
The stock has a 50-day simple moving average of $2.02 and a 200-day simple moving average of $2.02.
About H-CYTE
H-CYTE, Inc, a biopharmaceutical company, develops and delivers various treatments for patients with chronic respiratory and pulmonary disorders in the United States. The company develops and implements treatment options in autologous cellular therapy to treat chronic lung disorders. It has a product supply agreement with Rion, LLC to develop and distribute a biologic for chronic obstructive pulmonary disease.
Featured Stories
- Five stocks we like better than H-CYTE
- The Risks of Owning Bonds
- Top 3 Reasons to Invest in This Bond ETF for Stability and Growth
- 3 Warren Buffett Stocks to Buy Now
- 2 Drone Stocks Surging from Increased Media Attention
- How to Invest in Small Cap Stocks
- Ciena Rebounds: AI and Strong Guidance Drive Post-Earnings Surge
Receive News & Ratings for H-CYTE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for H-CYTE and related companies with MarketBeat.com's FREE daily email newsletter.
